Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) just unveiled an update.
Vitrafy Life Sciences has scheduled an investor briefing to discuss its recently announced Strategic Commercial Agreement with IMV Technologies, highlighting the importance of the partnership and providing a forum for investors to ask questions. The company is using the session to deepen engagement with the market and explain how the agreement may support the commercial rollout and adoption of its cryopreservation technologies across multiple high-value biomedical and agricultural sectors.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.10 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited (ASX: VFY) is a life sciences company that has developed advanced cryopreservation technology designed to significantly improve cell survival rates across applications such as blood platelets, cell and gene therapies, aquaculture and bovine reproduction. It delivers complete cryopreservation solutions through a managed service revenue model built around FDA-registered Smart Freezing and Smart Thawing devices, its integrated LifeChain software platform and Smart Packaging systems.
Average Trading Volume: 25,202
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$83.64M
Find detailed analytics on VFY stock on TipRanks’ Stock Analysis page.